YSP Southeast Asia Holding Bhd - Asset Resilience Ratio
YSP Southeast Asia Holding Bhd (7178) has an Asset Resilience Ratio of 27.37% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 7178 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how YSP Southeast Asia Holding Bhd's Asset Resilience Ratio has changed over time. See 7178 net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down YSP Southeast Asia Holding Bhd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 7178 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | RM148.10 Million | 27.37% |
| Short-term Investments | RM0.00 | 0% |
| Total Liquid Assets | RM148.10 Million | 27.37% |
Asset Resilience Insights
- Very High Liquidity: YSP Southeast Asia Holding Bhd maintains exceptional liquid asset reserves at 27.37% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
YSP Southeast Asia Holding Bhd Industry Peers by Asset Resilience Ratio
Compare YSP Southeast Asia Holding Bhd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Cipla Limited
NSE:CIPLA |
Drug Manufacturers - Specialty & Generic | 20.75% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.92% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 11.00% |
Annual Asset Resilience Ratio for YSP Southeast Asia Holding Bhd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for YSP Southeast Asia Holding Bhd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 15.16% | RM80.14 Million ≈ $20.12 Million |
RM528.74 Million ≈ $132.75 Million |
+5.28pp |
| 2023-12-31 | 9.87% | RM51.41 Million ≈ $12.91 Million |
RM520.74 Million ≈ $130.74 Million |
-17.45pp |
| 2022-12-31 | 27.32% | RM129.51 Million ≈ $32.51 Million |
RM474.05 Million ≈ $119.02 Million |
+0.43pp |
| 2021-12-31 | 26.89% | RM120.40 Million ≈ $30.23 Million |
RM447.75 Million ≈ $112.42 Million |
+17.54pp |
| 2020-12-31 | 9.35% | RM41.94 Million ≈ $10.53 Million |
RM448.74 Million ≈ $112.66 Million |
-2.11pp |
| 2019-12-31 | 11.46% | RM49.47 Million ≈ $12.42 Million |
RM431.74 Million ≈ $108.39 Million |
+0.72pp |
| 2018-12-31 | 10.74% | RM44.28 Million ≈ $11.12 Million |
RM412.41 Million ≈ $103.54 Million |
-9.59pp |
| 2017-12-31 | 20.32% | RM75.20 Million ≈ $18.88 Million |
RM370.01 Million ≈ $92.90 Million |
+9.54pp |
| 2016-12-31 | 10.79% | RM36.80 Million ≈ $9.24 Million |
RM341.10 Million ≈ $85.64 Million |
-- |
About YSP Southeast Asia Holding Bhd
Y.S.P. Southeast Asia Holding Berhad, together with its subsidiaries, engages in the manufacturing and trading of generic drugs in Malaysia, Singapore, Vietnam, Philippines, Cambodia, Myanmar, Brunei, Indonesia, Thailand, Africa, and internationally. It operates through three segments: Manufacturing, Trading, and Investment Holding. The company manufactures, sells, imports, exports, trades in, an… Read more